RichardL.WassermanMDPhD

PubMed

• 1 citations
  Oral immunotherapy in US allergy practice.
  Wasserman, R., Windom, H., Jones, D.> ;The Journal of Allergy and Clinical Immunology. in Practice. 2023 Dec 1
• 1 citations
  Development of a novel shared decision making aid for primary immunodeficiency diseases.
  Spiros Tzivelekis, Jordan Orange, Christine Poulos, Lisa M Meckley, Holly Peay, Jessie Sutphin, Vivian P Hernandez-Trujillo, Richard L Wasserman> ;Immunotherapy. 2023 Jun 1
• Accelerating Food Allergy Research: Need for a Data Commons.
  Ruchi S Gupta, Shruti Sehgal, Mark Wlodarski, Lucy A Bilaver, Firas H Wehbe, Jonathan M Spergel, Julie Wang, Christina E Ciaccio, Sai R Nimmagadda, Amal Assa'ad, Mahbo...> ;The Journal of Allergy and Clinical Immunology. in Practice. 2023 Apr 1
• Reply to high cost of immunoglobulin replacement therapy: Causes and implications.
  Richard L Wasserman> ;Annals of Allergy, Asthma & Immunology. 2023 Feb 1
• 1 citations
  Traveling with primary immunodeficiency.
  Richard L Wasserman> ;Annals of Allergy, Asthma & Immunology. 2023 Apr 1
• 2 citations
  Systemic IgG exposure and safety in patients with primary immunodeficiency: a randomized crossover study comparing a novel investigational wearable infusor versus the ...
  Richard L Wasserman, Charlotte Cunningham-Rundles, John Anderson, Patricia Lugar, Michael Palumbo, Niraj C Patel, Jutta Hofmann, Fiona Glassman, Eileen Rogers, Michael...> ;Immunotherapy. 2022 Nov 1
• 8 citations
  Information needs of patients considering oral immunotherapy for food allergy.
  Douglas Paul Mack, Matthew Greenhawt, Paul J Turner, Richard L Wasserman, Mariam A Hanna, Marcus Shaker, Sarah W Hughes, Pablo Rodríguez Del Río> ;Clinical and Experimental Allergy. 2022 Dec 1
• 2 citations
  Immunoglobulin replacement therapy stewardship in modern times.
  Richard L Wasserman> ;Annals of Allergy, Asthma & Immunology. 2022 Nov 1
• 1 citations
  Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases.
  Richard L Wasserman, Sudhir Gupta, Mark Stein, Christopher J Rabbat, Werner Engl, Heinz Leibl, Leman Yel> ;Immunotherapy. 2022 Mar 1
• 3 citations
  Towards an FDA-cleared basophil activation test.
  Oral Alpan, Richard L Wasserman, Theodore Kim, Amy Darter, Atul Shah, Douglas Jones, Donald McNeil, Henry Li, Laura Ispas, Melinda Rathkopf, Elena Perez, Dareen Siri, ...> ;Frontiers in Allergy. 2022 Jan 1
• 1 citations
  Immunoglobulin replacement for primary immunodeficiency: Indications for initiating and continuing treatment.
  Richard L Wasserman> ;Allergy and Asthma Proceedings. 2021 Nov 1
• 2 citations
  Oral Immunotherapy-Related Awareness, Attitudes, and Experiences Among a Nationally Representative Sample of Food Allergy Patients/Caregivers.
  Christopher M. Warren, Anita Roach, Rajeshree Das, Thomas B. Casale, Brian P. Vickery, Richard L. Wasserman, Ruchi Gupta> ;The Journal of Allergy and Clinical Immunology. in Practice. 2021 Jul 29
• 2 citations
  Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies.
  Elena E. Perez, Jacques Hébert, Anne K. Ellis, Oral Alpan, William R. Lumry, Ralph Shapiro, Daniel Suez, J. Fernando Mandujano, Richard L. Wasserman> ;Frontiers in Immunology. 2021 Jul 8
• 14 citations
  An Approach to the Office-Based Practice of Food Oral Immunotherapy
  Richard L. Wasserman, Jeffrey M. Factor, Hugh H. Windom, Elissa M. Abrams, Philippe Bégin, Edmond S. Chan, Matthew Greenhawt, Nathan Hare, Douglas P. Mack, Lyndon E. M...> ;The Journal of Allergy and Clinical Immunology. in Practice. 2021 May 1
• 1 citations
  Exploiting nut cross-reactivity to facilitate real-world treatment of tree nut allergy.
  Richard L. Wasserman, Hugh H. Windom, Daria Lie, Deanna M. Pence, Jean Ly> ;Annals of Allergy, Asthma & Immunology. 2021 Apr 10
• 6 citations
  Validation of inducible basophil biomarkers: Time, temperature and transportation.
  Theodore Kim, Jing Yu, Henry Li, Mark D. Scarupa, Richard L. Wasserman, Athena Economides, Martha V. White, Carla Ward, Atul Shah, Douglas H. Jones, Melinda Rathkopf, ...> ;Cytometry. Part B, Clinical Cytometry. 2021 Feb 4
• 4 citations
  Microbiological, Physicochemical, and Immunological Analysis of a Commercial Cashew Nut-Based Yogurt.
  Christopher P. Mattison, Kayanush J. Aryana, Kristen Clermont, Eric Prestenburg, Steven W. Lloyd, Casey C. Grimm, Richard L. Wasserman> ;International Journal of Molecular Sciences. 2020 Nov 4
• 23 citations
  Consensus report from the Food Allergy Research & Education (FARE) 2019 Oral Immunotherapy for Food Allergy Summit.
  Amber N. Pepper, Amal Assa'ad, Michael S. Blaiss, Emily Brown, Sharon Chinthrajah, Christina E. Ciaccio, Mary Beth Fasano, Ruchi Gupta, Nurry Hong, David M. Lang, Todd...> ;The Journal of Allergy and Clinical Immunology. 2020 Aug 1
• Common variable immunodeficiency and respiratory complications: take-home messages for the clinician.
  Richard L. Wasserman> ;Annals of Allergy, Asthma & Immunology. 2020 May 1
• 6 citations
  Clinical Practice Experience with HyQvia in Adults Using Alternative Dosing Regimens and Pediatric Patients: A Retrospective Study.
  Richard L. Wasserman> ;Advances in Therapy. 2020 Mar 2
• Captaining the PIDD ship.
  Richard L. Wasserman> ;Annals of Allergy, Asthma & Immunology. 2019 Nov 1
• 6 citations
  Manufacturing process optimization of ADMA Biologics' intravenous immunoglobulin products, BIVIGAM® and ASCENIV™.
  Richard L. Wasserman, Daniel Garcia, Benjamin N Greener, Kaitlin M. Kestenberg, Adam Pinkert, James Mond, Adam S. Grossman> ;Immunotherapy. 2019 Oct 9
• 2 citations
  The real world is not standardized.
  Richard L. Wasserman, Angela R. Hague, Deanna M. Pence, Robert W. Sugerman, Stacy K. Silvers, Joanna G. Rolen, Morley Herbert> ;The Journal of Allergy and Clinical Immunology. in Practice. 2019 Jul 1
• 12 citations
  Reaching for best practices in food oral immunotherapy: Report on the second annual Food Allergy Support Team meeting.
  Richard L. Wasserman, Douglas H. Jones, Hugh H. Windom, Meeting Faculty> ;Annals of Allergy, Asthma & Immunology. 2019 May 11
• 77 citations
  Real-World Experience with Peanut Oral Immunotherapy: Lessons Learned From 270 Patients.
  Richard L. Wasserman, Angela R. Hague, Deanna M. Pence, Robert W. Sugerman, Stacy K. Silvers, Joanna G. Rolen, Morley A. Herbert> ;The Journal of Allergy and Clinical Immunology. in Practice. 2019 Feb 1
• Join now to see all

Journal Articles

• Efficacy of Human C1-Esterase Inhibitor (C1-INH) concentrate compared to placebo in acute abdominal hereditary angioedema attacks.  
  Craig TJ, Levy RJ, Wasserman RL, et al, J Allerg Clin Immunol, 104(4), 801-808
• Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies.  
  Yong, Pierre L & Boyle, John & Ballow, Mark & Boyle, Marcia & Berger, Melvin & Bleesing, Jack & Bonilla, Franciso A & Chinen, Javier & Cunninghamm-Rundles, Charlotte &..., Clin Immunol. 135(2):255-63
• 2010 Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema.  
  Craig TJ, Wasserman RL, Levy RJ, Bewtra AK, Schneider L, Packer F, Yang W, Keinecke HO, Kiessling PC, J Clin Immunol. 30:823–829
• Pharmacokinetics and Safety of Subcutaneous Immune Globulin (Human), 10% Caprylate/Chromatography Purified in Patients With Primary Immunodeficiency Disease.  
  R L Wasserman, Irani AM, Tracy J, Tsoukas C, Stark D, Levy R, Chen J, Sorrells S, Roberts R, Gupta S, Clin Exp Immunol. 161(3), 518–526
• Orange JS 2010 Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.  
  JB Hagan, Fasano MB, Spector S, Wasserman RL, Melamed I, Rojavin MA, Zenker O, J Clin Immunol. 30(5):734-45
• Population Pharmacokinetics of Plasma-Derived C1 Esterase Inhibitor Concentrate Used to Treat Acute Hereditary Angioedema Attacks.  
  Bernstein JA, Ritchie B, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz DS, Obtulowicz K, Reshef A, Moldovan D, Shirov T, Grivcheva-Panovska V, Kiessling PC, Schindel F, C..., Ann Allergy Asthma Immunol. 105(2):149-54
• Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks.  
  RL Wasserman, Levy RJ, Bewtra AK, Hurewitz D, Craig TJ, Kiessling PC, Keinecke HO,Bernstein JA, Ann Allergy Asthma Immunol. 106(1): 62-68
• Pharmacokinetics of Subcutaneous IgPro20 in patients with primary immunodeficiency.  
  Wasserman RL, Melamed I, Nelson RP, Knutsen AP, Fasano MB, Stein MR, Rojavin MA, Kiessling P, Church JA, Clin Pharmacokinet. 50(6): 405-414
• Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunod...  
  Wasserman RL, Melamed I, Kobrynski L, Strausbaugh SD, Stein MR, Sharkhawy M, Engl W, Leibl H, Sobolevsky L, Gelmont D, Schiff RI, Grossman WJ, J Clin Immunol. 2011 Jun;31(3):323-31
• Human pasteurized C1 esterase inhibitor concentrate in 1085 hereditary angioedema attacks - final results of the open-label extension study.  
  Craig TJ, Bewtra AK, Bahna SL, Hurewitz D, Schneider L, Levy R, Moy J, Offenberger J, Jacobson KW, Yang W, Eidelman F, Janss G,Packer F, Rojavin MA, Machnig T, Keineck..., I.M.P.A.C.T.2. 2011 Allergy. 2011 Sep 2. doi: 10.1111/j.1398-9995.2011.02702.x
• Safety, Efficacy And Pharmacokinetics Of A New 10% Liquid Intravenous Immunoglobulin (Bivigam™ IVIG) In Patients With Primary Immunodeficiency.  
  Wasserman RL,Church J, Stein M, Moy J, White M, Strausbaugh S, Schroeder H, Ballow M, Harris M, Melamed I, Elkayam D, Lumry W, Suez D, Rehman SM, J Clin Immunol. 2012 Aug;32(4):663-9
• Safety of L-proline as a stabilizer for immunoglobulin products.  
  Hagan JB, Wasserman RL, Baggish J, Spycher M, Berger M, Shashi V, Lohrmann E, Sullivan K, Expert Rev Clin Immunol 8(2) 169-187
• Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy.  
  Orange JS, Belohradsky BH, Berger M, Borte M, Hagan J, Jolles S, Wasserman RL, Baggish JS, Saunders R, Grimbacher B, Clin Exp Immunology. 2012: 169:172-181
• Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.  
  Craig TJ, Bewtra AK, Hurewitz D, Levy R, Janss G, Jacobson KW, Packer F, Bernstein JA, Rojavin MA, Machnig T, Keinecke OH, Wasserman RL, Asthma and Allergy Proc. 33:354-61
• Novel Method of Subcutaneous Immunoglobulin Administration Facilitated by Recombinant Human Hyaluronidase: A Phase Three Clinical Study of Efficacy, Tolerability and P...  
  Wasserman RL, Melamed I, Stein MR, Engl W, Leibl H, McCoy B, Empson VG, Gelmont D, Schiff RI and the IGSC, 10% with rHuPH20 Study Group, J. Allergy Clin Immunol. 2012. 130:951-57
• C1-INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. studies.  
  Schneider L, Hurewitz D, Wasserman R, Obtulowicz K, Machnig T, Moldovan D, Reshef A, Craig TJ, Pediatr Allergy Immunol. 2013 Feb;24(1):54-60. doi: 10.1111/pai.12024
• Per-Attack Reporting of Prodromal Symptoms Concurrent with C1-Inhibitor Treatment of Hereditary Angioedema Attacks.  
  Prematta M, Bewtra AK, Levy RJ, Wasserman RL, Jacobson KW, Machnig T, Craig T, Adv Ther, 1-10. DOI 10.1007/s12325-0053-5
• C1-inhibitor therapy for hereditary angioedema attacks: Prospective patient assessments of health-related quality of life.  
  Bewtra AK, Levy RJ, Jacobson KW, Wasserman RL, Machnig T, Craig TJ, Allergy and Asthma Proc. 33:427-431
• Transfusion-associated cytomegalovirus infection and acquired immune deficiency syndrome in an infant.  
  Shannon K, Ball E, Wasserman RL, Murphy FK, Luby J, Buchanan GR, J. Pediatr. 103:859-863
• Ataxia -Telangectasia associated with sarcoidosis.  
  Fleck RM, Meyers LK, RL Wasserman, Tigelaar RE, Freeman RG, Pediatr. Derm. 3:339-343
• HIV infection detected by the PCR in an agammaglobulinemic patient.  
  Young KKY, Peter JB, Wasserman RL, AIDS 4:468-469
• Cephaloskeletal dysplasia (Tabyi-Linder syndrome; osteodysplastic primordial dwarfism type III): report of two cases and a review of the literature.  
  Vichi GF, Currarino G, Wasserman RL, Duvina PL, Filippi L, Pediatr Radiol 30:644-652
• Office-based oral immunotherapy for food allergy is safe and effective.  
  Wasserman RL, Sugerman RW, Mireku-Akomeah N, Mansfield L, Baker JW, J Allergy Clin Immunol. 2011 Jan;127(1):290-1; author reply 291-2
• Neonatal Sepsis: The Potential of Granulocyte Transfusion.  
  Wasserman RL, Hospital Practice 17:95-104
• Monoclonal Antibodies: Progress and Promise.  
  Polin RA, Wasserman RL, Lab. Manage. 21:33-38,40,43,44
• Join now to see all

Books/Book Chapters

• Pharmacokinetics of a new 10% Intravenous Immunoglobulin. 
  Chapter: Pharmacokinetics of a new 10% Intravenous Immunoglobulin 
  Page 272 - 278Wasserman RL, Church JA, Peter HH, et.alEur J Pharm Sci 37, 28
• Structure and evolution of immunoglobulin heavy chain variable regions. 
  Page 3 - 18Capra JD, Wasserman RL, Querinjean P, Kehoe JMFEBS Proceedings, Budapest
• The Glycoconjugates. 
  Chapter: Immunoglobulins 
  Wasserman RL, Capra JDEditors: MI Horowitz, W Pigman.Academic Press, New York
• Biological Basis of Immunodeficiency. 
  Chapter: Primary structural conservation in the evolution of IgM 
  Page 169 - 176McCumber LJ, Wasserman RL, Capra JDEditors: EW Gelfand, HM Dosch.Raven Press, New York
• Immunohematology. 
  Chapter: Monoclonal Antibodies: Production and Use 
  Wasserman RLEditors: E. Steane.American Dade, Miami
• Current therapy in pediatric infectious disease. 
  Chapter: Chronic granulomatous disease 
  Page 275 - 279Wasserman RLEditors: JD Nelson.B.C. Decker Inc, Toronto
• Current therapy in pediatric infectious disease. 
  Chapter: Antibody deficiency states 
  Page 271 - 275Wasserman RLEditors: JD Nelson.B.C. Decker Inc., Toronto
• Human disease: Autoimmunity and human heavy chain variable regions. 
  Chapter: Polymorphism’s of immunologically relevant loci 
  Page 378 - 382Sanz I, RL Wasserman, Hwang LY, Hasemann C, Thomas J, Tucker P, Capra JDEditors: F. Morriss.Quality Medical Publishing Inc., St. Louis
• Essentials Pediatric Intensive Care. 
  Chapter: Immunologic Disorders 
  Page 172 - 174Wasserman RLEditors: D Levin and F Morriss.Quality Medical Publishing, Inc., St. Louis
• 1001 Healthy Baby Answers. 
  Chapter: Asthma 
  Page 93 - 98Wasserman RLEditors: GC Morchower.Sourcebooks, Inc, Naperville, IL
• 1001 Healthy Baby Answers. 
  Chapter: Food Allergy 
  Page 262 - 267Wasserman RLSourcebooks, Inc, Naperville, IL
• Join now to see all

Abstracts/Posters

• Add-on omalizumab in children with uncontrolled moderate-severe allergic (IgE-mediated) asthma significantly reduces exacerbation rates.
  Milgrom H, Wasserman RL, Fowler-Taylor A, et al, 2009 ATS Annual Conference
• Oral Peanut Immunotherapy (OPI) in the Allergy Office.
  Mansfield LE, Wasserman R, Hutteman HR, Ruvalcaba M, Galluci A, ACAAI Annual Meeting 2009
• Patients Receiving C1-INH Treatment for Hereditary Angioedema Report Few Health-Related Limitations on Quality of Life Survey.
  Bewtra A, Levy R, Wasserman R, Jacobson K, Craig T, ACAAI Annual Meeting 2009
• Patient Data Capture System Reports Effectiveness of C1-INH Therapy for Acute Attacks of Hereditary Angioedema.
  Levy R, Bewtra A, Jacobson K, Wasserman R, Craig T, ACAAI Annual Meeting 2009
• Evaluation of Prodromal Symptoms Concurrent with Hereditary Angioedema Therapy.
  Prematta MJ, Craig T, Bewtra A, Levy R, Wasserman R, Jacobson K, Laudadio C, ACAAI Annual Meeting
• Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with PID.
  Hagan JB, Fasano MB, Spector S, Wasserman RL, Melamed I, Rojavin MA, Zenker O, Orange JS, AAAAI 2010 International Conference
• Pharmacokinetics of IgPro20 after subcutaneous administration in patients with PID.
  Wasserman RL, Melamed I, Nelson RP, Knutsen AP, Fasano MB, Stein MR, Rojavin MA, Kiessling,P, Church J, AAAAI 2010 International Conference
• Pharmacokinetics and Safety of Subcutaneous Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients With Primary Immunodeficiency Disease (...
  Wasserman RL, Irani AM,Gupta S, Tracy J, Tsoukas C, Stark D, Levy R, Roberts R, AAAAI 2010 International Conference
• Population Pharmacokinetics of C1 Esterase Inhibitor Used to Treat Patients with Acute Hereditary Angioedema Attacks in a Multicenter, Randomized, Placebo-controlled S...
  Ritchie B, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz DS, Obtulowicz K, Reshef A, Moldovan D, Shirov T, Grivcheva-Panovska V, Bernstein JA, Kiessling PC, Schindel F, C..., AAAAI 2010 International Conference
• C1 Esterase Inhibitor: Retrospective Validation of a Commonly Used Endpoint in Hereditary Angioedema Studies, Time to Onset of Relief, in a Global, Multicenter, Random...
  Bernstein JA, Ritchie B, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz DS, Obtulowicz K, Reshef A, Moldovan D, Shirov T, Grivcheva-Panovska V, Kiessling PC, Schindel F, C..., AAAAI 2010 International Conference
• IGIV 10%, Infused Intravenously and Subcutaneously to Subjects with Primary Immunodeficiency Diseases – Efficacy, Tolerability and Pharmacokinetic Comparison.
  Leibl H,Wasserman RL,Stein M, Melamed I, Schiff RI and the IGIV SC study group, First North American Primary Immune Deficiency Conference, 2010
• A prospective study (I.M.P.A.C.T.2) of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema.
  TJ Craig, Wasserman TL, Levy RJ, Bewtra AK, Schneider L, Packer F, Yang W, Keinecke HO, Kiessling PC, EAACI Annual Meeting, 2010
• Office Based Oral Desensitization of Patients With Anaphylactic Sensitivity to Foods Is Safe and Effective.
  Wasserman RL, Mansfield LE, Gallucci AR, Hutteman HR, Ruvalcaba AM, Long NA, Pence DM, AAAAI 2010 International Conference
• Office Based Oral Desensitization of Patients With Non-Anaphylactic Sensitivity to Foods Is Safe and Effective.
  Gallucci AR, Wasserman RL, Mansfield LE, Hutteman HR, Ruvalcaba AM, Long NA, Pence DM, AAAAI 2010 International Conference
• Tolerability of Human Immunoglobulin 10% Administered Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Patients with Primary Imm...
  Gelmont D, Wasserman RL, Melamed I, Stein M, Rubinstein A, McCoy B, Engl W, Leibl H, Schiff RI, Grossman WJ, AAAAI 2011 International Conference
• Oral Immunotherapy (OIT) of Food Allergy (FA) Successfully Desensitizes Most Patients.
  Gallucci AR, Wasserman RL, Sugerman RW, Mireku-Akomeah N, Pence DM, Long NA, AAAAI 2011 International Conference
• Peanut Oral Immunotherapy (OIT) of Food Allergy (FA) Carries a Significant Risk of Eosinophilic Esophagitis (EoE).
  Wasserman RL, Sugerman RW, Mireku-Akomeah N, Gallucci AR, Pence DM, Long NA, AAAAI 2011 International Conference
• Subcutaneous Immunoglobulin Replacement Therapy for Primary Immunodeficiency: High-Dose versus Low-Dose Treatment using Hizentra.
  Hagan J, Wasserman RL, Zenker O, Borte M, AAAAI 2011 International Conference
• New Immune Globulin Subcutaneous (Human), 10% (IGSC) Product is Well Tolerated in Subjects with Primary Immunodeficiency Diseases (PIDD).
  Grossman WJ, Wasserman RL, Melamed I, Stein M, Leibl H, Schiff RI, Gelmont D, AAAAI 2011 International Conference
• Pharmacokinetic Analysis (PK) of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficienc...
  Leibl H, Wasserman RL, Melamed I, Stein M, Engl W,Schiff RI, Gelmont D, Grossman WJ, AAAAI 2011 International Conference
• Efficacy Analysis of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (...
  Schiff RI, Wasserman RL, Melamed I, Stein M, Engl W, Leibl H,Gelmont D, AAAAI 2011 International Conference
• Pharmacokinetics (PK) of Human Immunoglobulin 10% Administered Subcutaneously Alone or Following Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency ...
  Rubinstein A, Wasserman RL, Melamed I, Stein M, McCoy B, Engl W, Leibl H,Gelmont D, Schiff RI, AAAAI 2011 International Conference
• Efficacy Analysis of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (...
  Schiff RI, Wasserman RL, Melamed I, Stein M, Engl W, Leibl H,Gelmont D, AAAAI 2011 International Conference
• Local Tolerability of Subcutaneous Infusions With 20% Immunoglobulin: Results From a Phase 3 Study in Subjects With Primary Immunodeficiency.
  Spector S, Wasserman RL, Melamed I, Rojavin MA, Hagan JB, Clinical Immunology Society Annual Meeting 2011
• Clinical Immunology Society Tolerability of Human Immunoglobulin 10% (IgG) Administered Subcutaneously (SC) or Facilitated With Recombinant Human Hyaluronidase (rHuPH2...
  Melamed I, Wasserman RL, Stein M, Rubinstein A, McCoy B, Engl W, Leibl H, Gelmont D, Schiff RI and the rHuPH20-facilitated IGSC Study Group, Clinical Immunology Society Annual Meeting 2011
• Join now to see all

Other

• Common Infusion-Related Reactions to Subcutaneous Immunoglobulin Therapy: Managing Patient Expectations. 
  Wasserman RL, Patient Preference and Adherence. 2008:2
  http://www.dovepress.com//common-infusion-related-reactions-to-subcutaneous-immunoglobulin-thera-pee